27th Feb 2026 07:30
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2026 as a result of the directed issue to Carl Bennet AB resolved on by Medivir on 5 February 2026. The issue has been previously announced through a separate press release. The new issue resulted in an increase of 90,000,000 ordinary shares.
Today, the last trading day of the month, there are in total 541,121,383 shares in Medivir, of which 538,671,220 ordinary shares and 2,450,163 class C-shares, which together carry 538,916,236.3 votes. One ordinary share entitles to one (1) vote and one class C-share entitles to one tenth (1/10) of a vote.
For additional information, please contact;Magnus ChristensenChief Financial OfficerMedivir ABPhone: +46 8 5468 3100Email: [email protected]
This information is information that Medivir is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-02-27 08:30 CET.
About MedivirMedivir develops innovative therapies targeting areas of high unmet medical need. Its drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir's two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (brittle bone disease). Both candidates have blockbuster potential, representing significant value creation opportunities for Medivir's shareholders and affected patients. Collaborations and partnerships play a key role in Medivir's business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com
AttachmentsPress Release (PDF)
Related Shares:
Medivir B Ord